James J. Keirns

5.0k total citations
88 papers, 3.9k citations indexed

About

James J. Keirns is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Infectious Diseases. According to data from OpenAlex, James J. Keirns has authored 88 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 17 papers in Cardiology and Cardiovascular Medicine and 16 papers in Infectious Diseases. Recurrent topics in James J. Keirns's work include Cardiac electrophysiology and arrhythmias (17 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Receptor Mechanisms and Signaling (9 papers). James J. Keirns is often cited by papers focused on Cardiac electrophysiology and arrhythmias (17 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Receptor Mechanisms and Signaling (9 papers). James J. Keirns collaborates with scholars based in United States, Japan and Netherlands. James J. Keirns's co-authors include Mark W. Bitensky, Donald N. Buell, Naomasa Miki, Donna Kowalski, David A. Erickson, Gary Mather, W. Trager, Robert Townsend, René H. Levy and Joshua A. Boyce and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemistry.

In The Last Decade

James J. Keirns

88 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James J. Keirns United States 34 1.5k 1.1k 875 486 464 88 3.9k
Stan G. Louie United States 40 773 0.5× 1.4k 1.3× 1.1k 1.3× 132 0.3× 395 0.9× 151 5.0k
Richard C. Brundage United States 38 1.5k 1.0× 452 0.4× 591 0.7× 170 0.3× 389 0.8× 136 3.8k
Johanna Weiß Germany 34 1.1k 0.7× 1.1k 1.0× 537 0.6× 193 0.4× 447 1.0× 167 4.4k
Mi‐Jeong Kim South Korea 28 887 0.6× 1.7k 1.6× 1.0k 1.1× 586 1.2× 241 0.5× 88 4.6k
Nicholas Murgolo United States 30 567 0.4× 1.8k 1.6× 476 0.5× 120 0.2× 257 0.6× 64 4.3k
Don K. Walker United Kingdom 22 374 0.3× 631 0.6× 194 0.2× 267 0.5× 216 0.5× 40 2.2k
Julia A. Balfour New Zealand 38 272 0.2× 1.1k 1.0× 877 1.0× 207 0.4× 821 1.8× 74 4.9k
Julie A. Stone United States 36 1.7k 1.1× 515 0.5× 735 0.8× 50 0.1× 427 0.9× 88 3.3k
Takahisa Furuta Japan 50 659 0.5× 1.5k 1.4× 976 1.1× 354 0.7× 546 1.2× 290 9.7k
W.S. Fred Wong Singapore 43 286 0.2× 2.6k 2.4× 487 0.6× 143 0.3× 329 0.7× 160 6.6k

Countries citing papers authored by James J. Keirns

Since Specialization
Citations

This map shows the geographic impact of James J. Keirns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Keirns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Keirns more than expected).

Fields of papers citing papers by James J. Keirns

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Keirns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Keirns. The network helps show where James J. Keirns may publish in the future.

Co-authorship network of co-authors of James J. Keirns

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Keirns. A scholar is included among the top collaborators of James J. Keirns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Keirns. James J. Keirns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Darpö, Börje, Charles Benson, Corina Dota, et al.. (2019). Evaluation of the Effect of 5 QT‐Positive Drugs on the JTpeak Interval — An Analysis of ECGs From the IQ‐CSRC Study. The Journal of Clinical Pharmacology. 60(1). 125–139. 3 indexed citations
2.
Keirns, James J., et al.. (2017). Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. Advances in Therapy. 34(12). 2625–2637. 20 indexed citations
3.
Malík, Marek, Katerina Hnatkova, Donna Kowalski, James J. Keirns, & E. Marcel van Gelderen. (2014). ICH E14‐Compatible Holter Bin Method and its Equivalence to Individual Heart Rate Correction in the Assessment of Drug‐Induced QT Changes. Journal of Cardiovascular Electrophysiology. 25(11). 1232–1241. 7 indexed citations
4.
Malík, Marek, Katerina Hnatkova, Donna Kowalski, James J. Keirns, & E. Marcel van Gelderen. (2013). QT/RR curvatures in healthy subjects: sex differences and covariates. American Journal of Physiology-Heart and Circulatory Physiology. 305(12). H1798–H1806. 46 indexed citations
5.
Roy, Michael J., et al.. (2013). Pharmacokinetics of Intravenous Conivaptan in Subjects With Hepatic or Renal Impairment. Clinical Pharmacokinetics. 52(5). 385–395. 6 indexed citations
6.
Zhang, Wenhui, et al.. (2013). Ipragliflozin Does Not Prolong QTc Interval in Healthy Male and Female Subjects: A Phase I Study. Clinical Therapeutics. 35(8). 1150–1161.e3. 7 indexed citations
7.
Mao, Zhongping Lily, et al.. (2011). Population Pharmacokinetics of Vernakalant Hydrochloride Injection (RSD1235) in Patients With Atrial Fibrillation or Atrial Flutter. The Journal of Clinical Pharmacology. 52(7). 1042–1053. 6 indexed citations
8.
Mao, Zhongping Lily, et al.. (2011). Disposition and Mass Balance of [<sup>14</sup>C]Vernakalant After Single Intravenous and Oral Doses in Healthy Volunteers. Drug Metabolism Letters. 5(2). 114–125. 9 indexed citations
9.
10.
Koning, P. de & James J. Keirns. (2009). Clinical Pharmacology, Biomarkers and Personalized Medicine: Education Please. Biomarkers in Medicine. 3(6). 685–700. 7 indexed citations
11.
Krueger, Gerald G., Lawrence F. Eichenfield, J. John Goodman, et al.. (2007). Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis.. PubMed. 6(2). 185–93. 23 indexed citations
12.
Hébert, Mary F., Robert Townsend, Stephen M. Austin, et al.. (2005). Concomitant Cyclosporine and Micafungin Pharmacokinetics in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(8). 954–960. 83 indexed citations
13.
14.
Hébert, Mary F., Helen Smith, Thomas Marbury, et al.. (2005). Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction. The Journal of Clinical Pharmacology. 45(10). 1145–1152. 136 indexed citations
15.
Riska, Paul, Michael Lamson, Thomas R. MacGregor, et al.. (1999). Disposition and Biotransformation of the Antiretroviral Drug Nevirapine in Humans. Drug Metabolism and Disposition. 27(8). 895–901. 174 indexed citations
16.
Hauss, David J., et al.. (1998). Lipid-Based Delivery Systems for Improving the Bioavailability and Lymphatic Transport of a Poorly Water-Soluble LTB4 Inhibitor. Journal of Pharmaceutical Sciences. 87(2). 164–169. 263 indexed citations
17.
Martin, Michael J., et al.. (1996). Effect of pronuclear dna microinjection on the development of porcine ova in utero. Theriogenology. 46(4). 695–701. 9 indexed citations
18.
Bitensky, Mark W., James J. Keirns, & John M. Freeman. (1973). Cyclic adenosine monophosphate and clinical medicine. The American Journal of the Medical Sciences. 266(5). 320–347. 12 indexed citations
19.
Keirns, James J., Peter Kreiner, & Mark W. Bitensky. (1973). An abrupt temperature‐dependent change in the energy of activation of hormone‐stimulated hepatic adenylyl cyclase. Journal of Supramolecular Structure. 1(4-5). 368–379. 7 indexed citations
20.
Kreiner, Peter, et al.. (1973). Hormonal control of melanocytes: MSH-sensitive adenyl cyclase in the Cloudman melanoma.. PubMed. 46(5). 583–91. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stan G. Louie Breakdown of academic impact, for papers by Richard C. Brundage Breakdown of academic impact, for papers by Johanna Weiß Breakdown of academic impact, for papers by Mi‐Jeong Kim Breakdown of academic impact, for papers by Nicholas Murgolo Breakdown of academic impact, for papers by Don K. Walker Breakdown of academic impact, for papers by Julia A. Balfour Breakdown of academic impact, for papers by Julie A. Stone Breakdown of academic impact, for papers by Takahisa Furuta Breakdown of academic impact, for papers by W.S. Fred Wong
Rankless by CCL
2026